|
|
Volumn 8, Issue 3, 2011, Pages 288-292
|
|
The continuing need for drug development and clinical trials in type 2 diabetes and its complications: Introduction to the RDS special issue
|
|
Author keywords
Antidiabetic; Extraglycemic effects; Incretin based therapy; SGLT 2 inhibitor; Type 2 diabetes
|
|
Indexed keywords
2,4 THIAZOLIDINEDIONE DERIVATIVE;
ANGIOTENSIN RECEPTOR ANTAGONIST;
ANTIDIABETIC AGENT;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
EXENDIN 4;
GLUCAGON;
GLUCAGON LIKE PEPTIDE 1;
GLUCOSE;
HEMOGLOBIN A1C;
INCRETIN;
INSULIN;
LIRAGLUTIDE;
METFORMIN;
MITOGEN ACTIVATED PROTEIN KINASE 1;
MITOGEN ACTIVATED PROTEIN KINASE 3;
PEPTIDE YY;
PHOSPHATIDYLINOSITOL 3 KINASE;
REACTIVE OXYGEN METABOLITE;
SAXAGLIPTIN;
SITAGLIPTIN;
SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;
SULFONYLUREA;
UNCLASSIFIED DRUG;
VILDAGLIPTIN;
ADD ON THERAPY;
ARTERY BLOOD FLOW;
BLOOD GLUCOSE MONITORING;
CARDIOVASCULAR FUNCTION;
CARDIOVASCULAR RISK;
CENTRAL NERVOUS SYSTEM;
CLINICAL TRIAL (TOPIC);
DISEASE DURATION;
DRUG DEVELOPMENT;
DRUG EFFECT;
EDITORIAL;
ENZYME ACTIVATION;
GLUCAGON RELEASE;
GLUCONEOGENESIS;
GLUCOSE ABSORPTION;
GLUCOSE BLOOD LEVEL;
GLUCOSE UTILIZATION;
HEALTH CARE COST;
HEART INFARCTION SIZE;
HEART MUSCLE ISCHEMIA;
HUMAN;
HYPERGLYCEMIA;
IMPAIRED GLUCOSE TOLERANCE;
INSULIN RELEASE;
INSULIN RESISTANCE;
LIFE EXPECTANCY;
LIFESTYLE MODIFICATION;
MORTALITY;
MYOCARDITIS;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NONHUMAN;
OBESITY;
PANCREAS ISLET ALPHA CELL;
PHASE 3 CLINICAL TRIAL (TOPIC);
PHYSICAL ACTIVITY;
QUALITY OF LIFE;
RISK FACTOR;
RISK REDUCTION;
SIGNAL TRANSDUCTION;
WEIGHT CONTROL;
WEIGHT REDUCTION;
|
|
EID: 84856016128
PISSN: 16136071
EISSN: 16140575
Source Type: Journal
DOI: 10.1900/RDS.2011.8.288 Document Type: Editorial |
|
Times cited : (1)
|
|
References (16)
|
